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Background: Tests of tumour treatment time effect in patients prescribed post-operative radiotherapy for
early breast cancer have focussed on time to start of radiotherapy rather than overall treatment time. The
START randomised trials of radiotherapy fractionation provide an opportunity to directly estimate the
effect of treatment acceleration.
Methods: Between 1986 and 2002, a total of 5861 women with early breast cancer were recruited into
the UK START pilot (START-P), START-A and START-B randomised trials. START-P and START-A tested
13 fractions of 3.0–3.3 Gy against 25 fractions of 2.0 Gy with a fixed treatment duration of 5 weeks for
all schedules; START-B tested 15 fractions of 2.67 Gy in 3 weeks against 25 fractions of 2.0 Gy over
5 weeks. Estimates of the effect of length of treatment for local–regional relapse and for a measure of late
normal tissue effects (change in photographic breast appearance, for patients following breast conserving
surgery) were obtained from Cox proportional hazards regression analyses stratified according to trial.
Results: At a median follow-up of 10 years, 444/5831 (7.6%) patients with data available had a local–
regional relapse, and 1135/3185 (35.6%) had mild or marked change in photographic breast appearance
by 5 years. Adjusting for prognostic factors, the estimate of the overall treatment time effect for local–
regional relapse was 0.60 Gy/day (95%CI 0.10 to 1.18 Gy/day, p = 0.02), and 0.14 Gy/day (95%CI 0.09
to 0.34 Gy/day, p = 0.29) for change in photographic breast appearance.
Conclusions: Combined analysis of the START trials generates the hypothesis that overall treatment time
is a significant determinant of local cancer control after adjuvant whole breast radiotherapy, with
approximately 0.6 Gy per day ‘wasted’ in compensating for tumour cell proliferation.
 2016 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 121 (2016) 420–423
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Convincing evidence for a time-factor in radiotherapy exists for
squamous carcinomas of the head and neck, where at least 0.6 Gy
per day of treatment is required to compensate for tumour cell
repopulation between fractions, including week-end breaks
[1–5]. There are no comparable tests of treatment time in patients
prescribed adjuvant radiotherapy following primary surgery for
early breast cancer, where studies are limited to exploring the
impact of treatment delay. Such sources include randomised trials
comparing concomitant versus sequential adjuvant chemo-
radiotherapy, representing a difference in time from surgery to
radiotherapy of 4 months or so (reviewed in [6]). One of threestudies reported better local control after concomitant chemo-
radiotherapy, but an excess of late telangiectasia after concomitant
therapy suggests a time-independent effect may have contributed
to the difference in outcome [7]. The only randomised trial testing
sequence of chemotherapy and radiotherapy directly had limited
power (N = 244) and reported no dependency of long-term local
relapse in irradiated breast on whether CMF chemotherapy or
breast radiotherapy was given first [8]. The evidence for an impact
of delay is not all negative, since a large retrospective cohort
analysis of the Surveillance, Epidemiology, and End Results (SEER)
Program studied >18000 US women with early stage breast cancer
aged >65 years treated 1991–2002 with breast conserving surgery,
radiotherapy but no chemotherapy, and this study reported a con-
tinuous association between the interval from breast conserving
surgery to radiotherapy and local recurrence risk [8–11].
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cancer, the Ontario and START-B trials of adjuvant whole breast
radiotherapy, tested schedules delivered in shorter overall treat-
ment time than the international standard of 50 Gy in 25 fractions
over 5 weeks [12,13]. The START-P and START-A trials were
designed to generate direct estimates of a/b for tumour control
and normal tissue effects while controlling overall treatment time,
and can be used to adjust for differences in dose-fractionation
between randomised groups in the START-B trial [12,14,15]. We
have used all three START trials to generate a crude estimate of
the effect of overall treatment time for tumour (local control)
[15–17]. Since there would be no expected time factor for late
adverse effects in schedules extending over 6–8 weeks, the photo-
graphic assessments of change in photographic breast appearance
were also tested using the same methods as for tumour control, to
act as a control [18].Materials and methods
Design, methods and results of the START pilot, A and B trials
have been published elsewhere [12,14–17]. The START pilot
(N = 1410) and START A trials (N = 2236) tested 3.0–3.3 Gy against
2.0 Gy fractions with overall treatment time fixed at 5 weeks,
allowing direct estimates of the fractionation sensitivity of breast
cancer. A meta-analysis of the START pilot and START A trials with
those of the START B trial (N = 2215) testing 15 fractions of 2.67 Gy
in 3 weeks against 25 fractions of 2.0 Gy over 5 weeks allowed esti-
mation of the possible change in treatment effect for a 3-week ver-
sus a 5-week schedule for local–regional relapse and for the
normal tissue effects endpoint of any change in photographic
breast appearance. Only patients who had breast conserving sur-
gery were eligible for the photographic assessments, which scored
change in breast appearance annually up to 5 years and then at
10 years in START-P and at 2 and 5 years in START A and B com-
pared with a post-surgery baseline photograph taken prior to start
of radiotherapy treatment [19].Statistical methods
Cox proportional hazards (PH) regression analyses of time to
local–regional relapse and time to any change in photographic
breast appearance were stratified by trial to allow for differences
in case mix among trials. Crude estimates of the proliferation effect
for each endpoint was obtained from separate Cox PH regression
models including terms for total dose (bDose), total dose x dose
per fraction (bDxd) and a dummy variable for treatment time (btime),
where 0 represents 5 weeks and 1 represents 3 weeks. The actual
length of radiotherapy treatment for each patient according to
reported start and finish dates was not used in the analysis,
although very few had major delays [16,17]. Parameter estimates
obtained from the Cox PH regression were then used in the follow-
ing formula to estimate the dose recovered per day due to prolifer-
ation (in 2.0 Gy equivalent fractions), assuming a 14-day time
difference between the 2 schedules in START trial B:
Dprolif ¼ btime=14bDose þ 2bDxd
Non-parametric bootstrap resampling was used to obtain bias-
corrected 95% confidence intervals (CI) of the Dprolif estimate.
Known prognostic factors were included in the Cox PH regression
models: age, type of primary surgery, radiotherapy to axilla or
supraclavicular fossa, tumour bed boost, adjuvant chemotherapy,
tamoxifen, pathological tumour size for local–regional relapse;
age, adjuvant chemotherapy, tamoxifen, radiotherapy to axilla or
supraclavicular fossa, breast size and surgical deficit for any changein photographic breast appearance. Tumour grade and nodal status
were not included in the model for local–regional relapse due to
the number of patients for which these variables were unknown.Results
Post-randomisation data were available for 5831 of the 5861
patients entered into the START pilot, START A and B trials, of
whom 444 were reported to have had a local–regional relapse
(402/4730 (8.5%) for all 5-week schedules combined and 42/1101
(3.8%) for the 3-week schedule); median follow-up was 10 years
overall. Scores for any change in photographic breast appearance
at 2 and/or 5 years were available for 3185 patients, of whom
1135 were scored as mild or marked change. Patient clinical and
treatment characteristics for the analysis dataset are shown in
Table 1 for the 5-week schedules versus the 3-week schedule.
There were some differences due to varying case mix between
the three START trials. The crude (unadjusted) estimate of
Dprolif for local–regional relapse was 0.65 Gy/day (95%CI 0.12 to
1.66 Gy/day). Adjusting for prognostic factors for local–regional
relapse (type of primary surgery, radiotherapy to axilla or supra-
clavicular fossa, tumour bed boost, adjuvant chemotherapy,
tamoxifen, pathological tumour size) in 5613 patients with data
available for all variables in the Cox PH regression model gave an
adjusted estimate of Dprolif for local–regional relapse of 0.60 Gy/day
(95%CI 0.10 to 1.18 Gy/day) (Table 2). Thus, the effect of overall
treatment time on local–regional control is statistically significant
(p = 0.02). Corresponding estimates of Dprolif for any change in pho-
tographic breast appearance were 0.17 Gy/day (95%CI 0.10 to
0.36 Gy/day) for the crude estimate, and 0.14 Gy/day (95%CI
0.09 to 0.34 Gy/day) adjusted for age, radiotherapy to axilla or
supraclavicular fossa, adjuvant chemotherapy, tamoxifen, breast
size and surgical deficit (Table 2). The effect of overall treatment
time on change in photographic breast appearance is not statisti-
cally significant (p = 0.29 for the adjusted estimate).Discussion
This is a hypothesis-generating study suggesting that treatment
time influences local outcome of adjuvant radiotherapy in breast
cancer. The literature referred to in the Introduction yields conflict-
ing results, most commonly based on the analysis of treatment
delay. Our investigation was prompted by a suggestion of lower
local–regional relapse rates after 40 Gy in 15 fractions over
3 weeks compared with 50 Gy in 25 fractions over 5 weeks
reported in START-B (estimate of absolute difference 12%, 95%
CI 26% to 10%). The START-B trial was powered for non-
inferiority and the observed effect was not statistically significant,
but the 95% confidence interval was more suggestive of lower
local–regional relapse rates (by up to 2.6%) than of a higher rate
for the 3-week schedule. This prompted further examination on
the grounds that the local–regional relapse rate was expected to
be higher after 40 Gy in 15 fractions than after 50 Gy in 25 frac-
tions, for the following reason. The a/b point estimate of 3.5 Gy
for local–regional tumour control in the START-P and START-A tri-
als applied to the START-B 40 Gy in 15 fractions schedule generates
an equivalent total dose delivered in 2.0 Gy fractions (EQD2 Gy)
that is closer to 45 Gy than 50 Gy, assuming no impact of treatment
time. The slope of the dose–response for local control rates >90% is
very shallow, so a large difference in local control could not be
expected, even for an EQD2 Gy 5 Gy lower than the Control group
receives. Assuming the slope of the dose–response curve at the 95%
level of local control is described by a gamma value 0.1–0.2 (ten
times shallower than at 50% levels of local control), the expected
absolute inferiority in local control would be 1 to 2%. So, the
Table 2
Crude and adjusted bootstrap estimates of the proliferation parameter for local–regional relapse and change in photographic breast appearance (dose recovered per day in 2.0 Gy
equivalent fractions).
Crude estimate (95%CI), Gy/day Adjusted estimate (95%CI),Gy/day
Local–regional relapse 0.65 (0.12 to 1.66) 0.60 (0.10 to 1.18)a
Any change in photographic breast appearancec 0.17 (0.10 to 0.36) 0.14 (0.09 to 0.34)b
a Adjusted for age, type of primary surgery, radiotherapy to axilla or supraclavicular fossa, tumour bed boost, adjuvant chemotherapy, tamoxifen, pathological tumour size.
b Adjusted for age, radiotherapy to axilla or supraclavicular fossa, adjuvant chemotherapy, tamoxifen, breast size, surgical deficit.
c Any change in photographic breast appearance includes mild or marked change (compared with pre-radiotherapy baseline).
Table 1
Characteristics of the 5831 patients included in the analyses for the 5-week schedules from all 3 START trials combined and the 3-week schedule from START trial B.
5-Week schedules N = 4730 (%)+ 3-Week schedule N = 1101 (%)+ Total N = 5831 (%)+
Age (years)
Mean (SD) 56.3 (10.4) 57.8 (9.5) 56.6 (10.2)
[range] [23.3–86.8] [30.9–82.9] [23.3–86.8]
Pathological tumour size (cm)
Mean (SD) 2.2 (1.6) 1.8 (1.0) 2.1 (1.5)
Tumour grade
1 898 (23.8) 309 (28.6) 1207 (24.9)
2 1853 (49.1) 527 (48.7) 2380 (49.0)
3 1020 (27.0) 246 (22.7) 1266 (26.1)
Unknown 959 19 978
Nodal status
Negative 2924 (71.7) 797 (75.1) 3721 (72.4)
Positive 1152 (28.3) 264 (24.9) 1416 (27.6)
Unknown 654 40 694
Type of primary surgery
Breast conserving surgery 4310 (91.1) 1009 (91.6) 5319 (91.2)
Mastectomy 420 (8.9) 92 (8.4) 512 (8.8)
Tumour bed radiotherapy boost
No 2089 (44.4) 652 (59.5) 2741 (47.2)
Yes 2618 (55.6) 444 (40.5) 3062 (52.8)
Unknown 23 5 28
Radiotherapy to axilla or supraclavicular fossa
No 4022 (85.4) 1015 (92.6) 5037 (86.8)
Yes 686 (14.6) 81 (7.4) 767 (13.2)
Unknown 21 5 26
Adjuvant chemotherapy
No 3469 (73.6) 864 (78.9) 4333 (74.6)
Yes 1245 (26.4) 231 (21.1) 1476 (25.4)
Unknown 16 6 22
Adjuvant tamoxifen
No 928 (19.7) 135 (12.3) 1063 (18.3)
Yes 3786 (80.3) 960 (87.7) 4746 (81.7)
Unknown 16 6 22
Breast size from baseline photograph*
Small 344/2847 (12.1) 37/454 (8.1) 381/3301 (11.5)
Medium 2068/2847 (72.6) 344/454 (75.8) 2412/3301 (73.1)
Large 435/2847 (15.3) 73/454 (16.1) 508/3301 (15.4)
Surgical deficit from baseline photograph*
Small 1701/2838 (59.9) 247/454 (54.4) 1948/3296 (59.1)
Medium 909/2838 (32.0) 162/454 (35.7) 1071/3296 (32.5)
Large 228/2838 (8.0) 45/454 (9.9) 273/3296 (8.3)
Unknown 9 0 9
+ %s calculated excluding unknowns.
* Baseline photographs available for 3301 of the 3185 patients who were in the photographic assessments sub-studies of the trials.
422 Tumour cell repopulation in breast cancerobserved 4.3% 10-year local–regional relapse rate after 40 Gy in 15
fractions is about 2.2 to 3.2 percentage points lower than
predicted, assuming no time effect. This is how the observed
non-inferiority of tumour control in START B raises the possibility
of a treatment time effect on tumour control, which our results
estimate to be 0.6 Gy per day (95%CI 0.10 to 1.18 Gy per day).
The main strength of this study is that it is based on data col-
lected systematically and prospectively in randomised trials that
pre-specified and quality-assured the delivery of radiotherapy
and ensured high compliance with collection of post-treatment
outcome data. The main weakness is that the estimate for a treat-
ment time effect is based on a single trial (START-B), given that theduration of treatment was 5 weeks for all schedules in the START-P
and START-A trials. In addition, although randomisation is the
most effective way of balancing prognostic variables between
treatment groups, small imbalances are inevitable, even in a trial
of >2000 patients. Whether or not the above factors apply here,
it is noteworthy that the Ontario trial testing 42.5 Gy in 16 frac-
tions of 2.7 Gy in 3.2 weeks whole breast radiotherapy against
50 Gy in 25 fractions did not detect any differences in long-term
outcome between schedules, either in terms of local tumour con-
trol (absolute difference, 1.5 percentage points; 95% CI 6.9 to
9.8) or breast cosmesis (absolute difference, 0.5 percentage points;
95% CI 2.5 to 3.5) [13]. It took only 19 days to deliver 15 fractions
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rupted, but on average, most patients started on another week-day
resulting in a treatment duration of 21 days compared with the
22 days needed to deliver 16 fractions in the Ontario trial. In other
words, the difference in treatment time between these two trials
could be closer to 1 day than 3 days. The different outcomes in
the START B and Ontario trials could possibly be due to differences
in the tumour characteristics of the populations tested in the two
trials, particularly tumour grade, or simply be a factor of the impre-
cision in the tumour control estimates.
If a treatment time effect for breast cancer is real and of the
magnitude estimated in this analysis, the implications are signifi-
cant. For patient populations suffering local relapse risks >10% fol-
lowing conventionally fractionated radiotherapy, the absolute
gains in local control from adopting a 3-week schedule are likely
to be clinically worthwhile, even without considering the lower
adverse event rates (e.g. HR 0.8, 95% CI 0.67 to 0.96 for breast
shrinkage) associated with this regimen in the START-B trial [12].
The implications for tumour bed boost dose regimens would be
that synchronous/concomitant boost would be more effective than
sequential boost techniques; this is the hypothesis tested in the UK
IMPORT HIGH and RTOG 1005 trials. For patient populations expe-
riencing local relapse risks <<10% after conventional fractionation,
the main benefit would be the reduced rate of late adverse events
reported after 40 Gy in 15 fractions, as described above [12].
The final point of discussion relates to the adjusted estimate of
0.14 Gy/day (95%CI0.09 to 0.34 Gy/day) as the time factor for late
change in photographic breast appearance. Assuming this is a real
effect (it is not statistically significantly different from zero,
p = 0.286), the difference between the estimates for local control
and for late effects still means that a therapeutic gain can be
achieved from shortening overall treatment time. In fact, testing
the one-sided hypothesis that the treatment time effect for sub-
clinical breast cancer exceeds that for late effects (measured by
photographic breast appearance in this analysis) yields a statisti-
cally significant p-value of p = 0.03. If there is a small, effect of
overall treatment time it could be explained by the distinction
between a ‘true’ late effect, which might not be expected to show
a time effect, from a ‘consequential’ late effect that is a result
(direct consequence) of healing by secondary intention of a severe
early effect, usually moist desquamation in inframammary and
other skin folds [20]. Telangiectasia is the most visible manifesta-
tion in the irradiated breast, but severe cases can be accompanied
by subcutaneous induration and atrophy impacting on breast
appearance. Numbers of events were too small to allow testing
of association between a time factor and breast size as a surrogate
for moist desquamation risk in the START-B trial. In the existing
literature, a time factor for telangiectasia has been reported by
Turesson, attributed to slow repair rather than repopulation [21].
More recently, two large randomised trials of radiotherapy in head
and neck cancer testing 60 Gy in 30 fractions delivered in 5 or in
6 weeks reported no significant time factor for late adverse effects
despite significantly higher rates of both early adverse effects and
local tumour control [1,2]. In conclusion, we consider the time fac-
tor for late effects in START-B to represent a reasonable negative
control for our analysis.
Conclusions
A meta-analysis of the START trials generates the hypothesis
that overall treatment time is a significant determinant of local
cancer control after adjuvant whole breast radiotherapy, with
approximately 0.6 Gy per day ‘wasted’ in compensating for tumour
cell proliferation. Independent replication is needed before this
observation can be used in support of accelerated schedules of
hypofractionated radiotherapy in breast cancer.Conflict of interest statement
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